FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used to produce a pharmaceutical kit for passive rabies immunization. Pharmaceutical kit placed in an acceptable package comprises: 1) a pharmaceutical composition comprising virus neutralizing anti-rabies single-domain antibodies in an effective amount and a pharmaceutically acceptable buffer solution up to 1 ml, wherein the virus neutralizing anti-rabies single-domain antibodies have an amino acid sequence SEQ ID NO.1; wherein an effective dose of virus neutralizing anti-rabies single-domain antibodies is a dose of not less than 150 ME activity, in lyophilized form; 2) a pharmaceutical composition comprising recombinant pseudo-adenovirus particles carrying a gene of virus neutralizing anti-rabies single-domain antibodies in an effective amount, a pharmaceutically acceptable buffer solution up to 1 ml; recombinant pseudo-adenovirus particles carrying a gene for virus neutralizing anti-rabies single-domain antibodies have a nucleotide sequence of a genetic insert SEQ ID NO.3, and an effective dose of recombinant pseudo-adenovirus particles carrying a gene of virus neutralizing anti-rabies single-domain antibodies is at least 5×108 PFU in 1 ml of a pharmaceutically acceptable solvent; 3) instructions for the administration of this pharmaceutical kit. Group of inventions also relates to the use of a pharmaceutical kit for passive rabies immunization.
EFFECT: use of this group of inventions provides emergency prevention of rabies through passive immunization by using the produced pharmaceutical compositions, action of which begins with 6 hours of administration and lasts up to 7 days.
2 cl, 12 ex, 4 tbl, 6 dwg
Title | Year | Author | Number |
---|---|---|---|
PREPARATION BASED ON NEUTRALIZING MONOCLONAL ANTIBODIES BINDING WITH GLYCOPROTEIN OF RABIES VIRUS | 2018 |
|
RU2711553C1 |
TRIMERISED SINGLE-DOMAIN ANTIBODY THAT SPECIFICALLY BINDS WITH GLYCOPROTEIN G OF RABIES VIRUS, NEUTRALISING RABIES VIRUS | 2013 |
|
RU2533802C1 |
GENETIC CONSTRUCT BASED ON AN OPTIMIZED GENE OF RABIES VIRUS CONSENSUS GLYCOPROTEIN FOR PREVENTING RABIES | 2018 |
|
RU2707544C1 |
NEUTRALIZING MONOCLONAL ANTIBODY BINDING TO RABIES VIRUS GLYCOPROTEIN G, DNA FRAGMENTS CODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2017 |
|
RU2718835C2 |
ANTIRABIC INACTIVATED EMULSION CULTURE VACCINE FOR PROPHYLACTIC IMMUNIZATION OF DOMESTIC CARNIVORES AND FARM ANIMALS | 2019 |
|
RU2722868C1 |
METHOD FOR DETERMINING SPECIFIC ACTIVITY OF ANTI-RABIES IMMUNOGLOBULIN ON CELL CULTURE USING ATOMIC FORCE MICROSCOPY | 2018 |
|
RU2688334C1 |
ANTIVIRAL SIMILAR MINI-ANTIBODY, NUCLEOTIDE SEQUENCE, EXPRESSING RECOMBINANT VIRAL VECTOR, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION OR THERAPY OF INFLUENZA TYPE A | 2013 |
|
RU2536956C1 |
ANTI-FLU NANOANTIBODY, RECOMBINANT VIRAL VECTORS AND PHARMACEUTICAL COMPOSITIONS FOR PROPHYLAXIS AND THERAPY OF A-TYPE FLU | 2011 |
|
RU2502745C2 |
NUCLEOTIDE SEQUENCE OPTIMIZED FOR EXPRESSION IN BACTERIA OF CONSENSUS GLYCOPROTEIN OF RABIES VIRUS | 2018 |
|
RU2717255C1 |
METHOD OF POST-EXPOSURE PREVENTION OF TICK-BORNE ENCEPHALITIS | 2017 |
|
RU2682677C2 |
Authors
Dates
2018-07-11—Published
2016-11-11—Filed